223 related articles for article (PubMed ID: 35769575)
1. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study
D'Amato M; Menzella F; Altieri E; Bargagli E; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Caruso C; Centanni S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Ori A; Simoni L; Boarino S; Vitiello G; Aliani M; Del Giacco S
Front Allergy; 2022; 3():881218. PubMed ID: 35769575
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Benci M; Boarino S; Schroeder JW
Respir Res; 2023 May; 24(1):135. PubMed ID: 37210543
[TBL] [Abstract][Full Text] [Related]
3. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
[TBL] [Abstract][Full Text] [Related]
4. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
[TBL] [Abstract][Full Text] [Related]
6. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study
Caruso C; Cameli P; Altieri E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Centanni S; D'Amato M; Del Giacco S; De Michele F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Caminati M; Vultaggio A; Zullo A; Rizzoli S; Boarino S; Vitiello G; Menzella F; Di Marco F
Front Med (Lausanne); 2022; 9():950883. PubMed ID: 36117962
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm
Senna G; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Schroeder JW; Vultaggio A; Rizzoli S; Zullo A; Boarino S; Palmisano M; Rossi A; Vitiello G; Centanni S
J Asthma Allergy; 2022; 15():1593-1604. PubMed ID: 36387835
[TBL] [Abstract][Full Text] [Related]
8. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
Matsuno O; Minamoto S
Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
[TBL] [Abstract][Full Text] [Related]
9. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE
Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266
[TBL] [Abstract][Full Text] [Related]
10. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
Pelaia C; Crimi C; Benfante A; Caiaffa MF; Campisi R; Candia C; Carpagnano GE; Carrieri I; D'Amato M; Detoraki A; Barbaro MPF; Lombardo N; Macchia L; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Ricciardi L; Scichilone N; Scioscia G; Spadaro G; Tondo P; Uletta Lionetti S; Valenti G; Vatrella A; Crimi N; Pelaia G
Respirology; 2024 Jun; ():. PubMed ID: 38847185
[TBL] [Abstract][Full Text] [Related]
11. Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.
Mansur AH
Respir Med Case Rep; 2022; 35():101559. PubMed ID: 34976716
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
13. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
Cameli P; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Schroeder JW; Senna G; Vultaggio A; Benci M; Boarino S; Menzella F
J Asthma Allergy; 2024; 17():273-290. PubMed ID: 38562251
[TBL] [Abstract][Full Text] [Related]
14. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
[TBL] [Abstract][Full Text] [Related]
16. Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
Le TT; Emmanuel B; Katial R; Tran TN; Kwiatek JJ; Cohen DS; Daniel SR; Cao Y; Shih VH; Melcón MG; Devouassoux G; Pelaia G;
J Asthma Allergy; 2024; 17():313-324. PubMed ID: 38595692
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.
Heffler E; Saccheri F; Bartezaghi M; Canonica GW
Clin Transl Allergy; 2020; 10():25. PubMed ID: 32607141
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
[TBL] [Abstract][Full Text] [Related]
19. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
